# Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

> **NCT01202747** · PHASE2,PHASE3 · COMPLETED · sponsor: **TearScience, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Chalazion
- Dry Eye Syndromes

## Interventions

- **DEVICE:** LipiFlow System

## Key facts

- **NCT ID:** NCT01202747
- **Lead sponsor:** TearScience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202747, "Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01202747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*